GlaxoSmithKline is trading 4.11% down at $48.85 in pre-market on October 28. Despite beating third-quarter sales and profit expectations, the stock is down due to several factors: - Vaccine sales fell 2% to £2.6 billion, with Shingrix down 5% and Arexvy declining 24% due to weaker market demand. - Total operating profit slid 16% and total EPS declined 21% due to a £328 million restructuring charge related to the Accelerate Growth program. - The company confirmed that full-year core EPS growth is expected at the lower half of its 7-9% guidance range, influenced by higher interest charges from the Nuvalent acquisition. - Barclays maintained a "Sell" rating, adding to the bearish sentiment.